Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
148
resultados
Última actualización
15/07/2026 [07:22:00]
Resultados 100 a 125 de 148
Resumen de: EP4756833A1
The invention discloses a diabetes management system for use in a hospital, including: at least a wearable medical device, a plurality of receivers, a central server and a healthcare provider terminal, the receivers receive the data information transmitted by the medical device and upload it to the central server, and the healthcare provider communicates with the central server and displays or reviews the medical data information through the terminal, as any one of the multiple receivers can receive the data information transmitted by the medical device and upload it to the central server, as a result, the patient's range of motion in the hospital is no longer restricted, which improves the patient's experience and keeps the patient in a comfortable mood, while the healthcare provider is able to know the patient's blood glucose level and/or insulin infusion state in real time through the healthcare provider terminal and deal with the abnormalities in a timely manner, so that the patient's blood glucose level can be maintained at a stable level.
Resumen de: WO2025029671A1
Disclosed herein are methods of treating a subject having diabetes with a population of cells expressing ISL1 and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety.
Resumen de: US2025049355A1
Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor and convert the sensor current generated by the continuous analyte sensor into digital signals, one or more processors configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.
Resumen de: EP3831293A1
The present disclosure relates to a continuous blood glucose measurement body attachment unit, and provides a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator so as to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip so as to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be more accurately measured.
Resumen de: WO2026114787A1
A method (100) for adjusting a first biomarker measurement, comprising: receiving (120) a first biomarker measurement from a subject; contemporaneously receiving (130) a time-dependent biomarker measurement from the subject; comparing (140) the time-dependent biomarker measurement to a subject-determined baseline; determining (150), based on the comparison, a time-warp of a baseline first biomarker measurement; and adjusting (160) the baseline first biomarker measurement by the determined amount of the time-warp to generate an adjusted first biomarker measurement.
Resumen de: US20260151572A1
Systems and methods are provided for a dual needle apparatus configured to couple to a reservoir of a syringe assembly with a luer lock fitting. The dual needle apparatus may include at least a first needle and a second needle, the first needle longer than the second needle. The first needle may be configured to deliver insulin from the reservoir to the interior of a medication bladder when inserted into the medication bladder. The second needle may be configured to release air or insulin from the medication bladder to an external environment responsive the pressure caused by insulin delivery through the first needle.
Resumen de: WO2026116775A1
Disclosed is a blood glucose measurement device capable of improving blood glucose measurement accuracy by focusing rays of light for blood glucose measurement in the measurement area of an object. According to an embodiment of the present invention, the blood glucose measurement device comprises: a light source unit disposed to output a plurality of first light rays for measuring blood glucose in the measurement area of an object; an optical unit including one or more optical bodies disposed to emit a plurality of first light rays toward the measurement area of the object; and a light-receiving unit disposed to receive a plurality of second light rays output through an interaction between the plurality of first light rays and the object. The one or more optical bodies include: a plurality of lenses arranged to condense a plurality of first light rays on the first surface of one or more optical bodies facing the light source unit; a reflective surface arranged to reflect a plurality of first light rays condensed by the plurality of lenses on the second surface of one or more optical bodies; and a refractive surface arranged to refract a plurality of first light rays reflected at the reflective surface toward the measurement area of the object on the third surface of one or more optical bodies.
Resumen de: US20260151056A1
0000 Techniques disclosed herein relate to calibrating glucose values. In some embodiments, the techniques may involve measuring one or more calibration values of an operating parameter of one or more monitor electrodes. The techniques may further involve determining one or more delta values using the one or more calibration values and one or more pre-calibration values, wherein the one or more delta values are indicative of a first reaction of a first chemistry stack of the one or more monitor electrodes. The techniques may further involve utilizing a relationship between a second reaction of a second chemistry stack disposed on one or more working electrodes and a first reaction of the first chemistry stack to translate the one or more delta values associated with the operating parameter of the one or more monitor electrodes to a change in an operating parameter of one or more working electrodes.
Resumen de: US20260151565A1
The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.
Resumen de: US20260151059A1
Analyte sensor apparatus, systems, and methods to reduce sensor drift. An analyte sensor apparatus (102) for detecting an analyte such as glucose in a target environment (10) such as a body tissue may include a plurality of electrodes and a controller. The plurality of electrodes may provide a plurality of electrode signals based on the target environment while disposed in the target environment. The controller may be operatively coupled to the plurality of electrodes and configured to receive the plurality of electrode signals. The controller may further be configured to adjust a voltage of at least one electrode of the plurality of electrodes based on a voltage profile to regenerate one or more electrodes of the plurality of electrodes while the at least one electrode is disposed in the target environment. This may allow to correct an electrode drift without removing the electrode from its target environment.
Resumen de: US20260151570A1
A method may include displaying at least three icons on a user interface of a mobile device, including a first icon associated with the at least three icons associated with a first carbohydrate level, a second icon associated with the at least three icons associated with a second carbohydrate level, and a third icon associated with the at least three icons associated with a third carbohydrate level. The method may also include receiving a user selection of one of the three icons through the user interface of the mobile device, and determining an insulin bolus level from the user selection. The method may also include communicating the insulin bolus level to an insulin delivery device.
Resumen de: WO2026114687A1
A method for identifying a deviation of a first biomarker measurement, comprising: receiving a first biomarker measurement from a subject at a first timepoint; comparing the received first biomarker measurement to a subject-determined baseline of first biomarker measurements; determining, based on the comparison, that the first biomarker measurement is a deviation from the subject-determined baseline of first biomarker measurements; and reporting the determined deviation of the first biomarker measurement.
Resumen de: WO2026114257A1
The present invention relates to a fusion protein and the use thereof. Specifically, provided in the present invention are a GCGR-IgG2/Fc fusion protein, a polynucleotide encoding the fusion protein, a vector and cell comprising the polynucleotide, and a composition thereof. The present invention also relates to the use of the fusion protein, polynucleotide, vector, cell and composition in a drug, and/or in the preparation of a drug for treating or preventing a glucose metabolism-related disease.
Resumen de: WO2025021960A1
The present invention relates to a biosensor for measuring the concentration of glucose and its use in glucose sensing. The biosensor of the present invention comprises a polymer comprising a boronic acid-based glucose-binding moiety, wherein said boronic acid-based glucose-binding moiety is immobilized in said polymer, and an inhibitor moiety, wherein said inhibitor moiety is immobilized in said polymer, and wherein said inhibitor moiety is capable of forming reversible crosslinks by binding to said boronic acid-based glucose-binding moiety. In the absence of glucose, the polymer is crosslinked by a bond formed between the boronic acid-based glucose-binding moiety and the inhibitor moiety. In the presence of glucose, the boronic acid-based glucose-binding moiety binds to glucose, whereby the bond between the boronic acid-based glucose-binding moiety and the inhibitor moiety is broken, which results in a change of volume of the polymer. The biosensor of the present invention is particularly useful for glucose monitoring performed on a subject under intensive care as well as in the situations wherein the glucose monitoring is performed on an unconscious subject.
Resumen de: WO2025021930A1
The present invention relates to a biosensor for measuring the concentration of glucose and its use in glucose sensing, wherein the biosensor comprising a polymer comprising the moiety of formula (I). The biosensor of the present invention is particularly useful for glucose monitoring performed on a subject under intensive care as well as in the situations wherein the glucose monitoring is performed on an unconscious subject.
Resumen de: CA2860107A1
The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.
Resumen de: RO139568A2
The invention relates to a portable measuring device allowing simultaneous electrochemical detection of lactate and glucose from sweat. According to the invention, the device comprises a small PC module (a) for instrument control, provided with software with graphical interface for representation and control of adjacent modules, namely: an electrochemical measuring module (b) provided with an analog multiplexing module (c) accommodating a screen-printed dual electrode array (d) mounted on wearable tapes that can be applied on the body and, in certain cases, a microfluidic module (e) that ensures sweat sampling and transfer to the measuring cell.
Resumen de: WO2026112485A1
The present disclosure is directed to a bio-feedback sensor in combination with AI and ML that can be implemented to optimize neuromodulation parameters for the management of a medical condition such a type II diabetes. The bio-feedback obtained by the sensors is optimized by the ML tools to predict and recommend the upregulation or downregulating the neuroregulators to modulate treatment. The algorithms could also learn to sense a life-threating pathological state, or bio-chemical imbalance, and in the case of diabetes a life-threating low blood sugar level the system overrides to stimulate the target fibers that control organs to regulate blood glucose levels.
Resumen de: US20260144928A1
0000 Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.
Resumen de: WO2026107792A1
A blood glucose management system, comprising: in a first operation mode, a program module (101) identifies the signal intensity of a broadcast signal; when the signal intensity of the broadcast signal is not less than a preset signal intensity threshold, the program module (101) establishes a wireless communication connection with a measurement module (100) and/or an infusion module (102) that sends the broadcast signal; in a second operation mode, a device identifier of the measurement module (100) and/or the infusion module (102) is inputted so as to establish the wireless communication connection.
Resumen de: WO2026109522A1
Apparatuses, systems, and techniques are described to integrate the operations of a computational platform with a third-party application. The computational platform can perform operations related to medical data and non-medical data. The medical data can be routed to services that comply with one or more first regulatory frameworks. The non-medical data can be routed to services that comply with one or more second regulatory frameworks. The medical data can be related to the treatment and care of diabetes.
Resumen de: US20260144933A1
The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.
Resumen de: US20260144934A1
0000 A portable infusion pump can communicate with glucose monitor, such as a continuous glucose monitor (CGM), to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Due to potential unreliability in the correlation of the CGM data to the user's actual blood glucose level, risk mitigation can be employed to limit the amount of extra insulin that can be delivered by the pump in response to the CGM data.
Resumen de: WO2026111961A1
Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.
Nº publicación: WO2026112174A1 28/05/2026
Solicitante:
UNIV WASHINGTON [US]
CIRULLI VINCENZINO [US]
LEVY SHIRI [US]
CRISA LAURA [US]
RUOHOLA BAKER HANNELE [US]
UNIVERSITY OF WASHINGTON
CIRULLI, Vincenzino
LEVY, Shiri
CRISA, Laura
RUOHOLA-BAKER, Hannele
Resumen de: WO2026112174A1
Methods are provided for generating pancreatic endocrine cells from pluripotent stem cells (PSCs) using epigenetic modifiers. A fusion protein comprising catalytically inactivated Cas9 (dCas9) and an embryonic ectoderm development (EED)-binding domain (EBdCas9) is used with guide RNAs (gRNAs) to target regulatory regions of transcriptional regulators including EOMES, PDX1, and NGN3. Sequential targeting of PDX1 and NGN3 promoters with EBdCas9 removes repressive H3K27me3 marks, increases activating H3K27ac modifications, and accelerates differentiation into insulin-producing β-cells. The methods significantly increase β-cell yields (~4-6 fold), reduce non-pancreatic lineage contaminants (CDX2+, SOX2+, enteroendocrine cells), enhance mitochondrial function, and produce glucose-responsive cells with superior functional maturation in vivo. The epigenetic interventions enforce pancreatic developmental fates while activating NGN3-dependent transcriptional programs necessary for endocrine cell differentiation, insulin secretion, and metabolic maturation. Cells and compositions produced by these methods are also provided.
BOPI
Sede Electrónica
